{"id":"placebo-subacute-phase","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3357550","moleculeType":"Small molecule","molecularWeight":"228.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance administered in the subacute phase of a Phase 3 trial to establish baseline disease progression and distinguish true drug efficacy from natural disease course or observer bias. It allows researchers to measure the actual therapeutic benefit of the investigational agent by comparison to a non-active control.","oneSentence":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:25.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06980805","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-02-19","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":56},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT06015737","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-29","conditions":"Cutaneous Lupus Erythematosus","enrollment":302},{"nctId":"NCT06013995","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-09-21","conditions":"Lupus","enrollment":44},{"nctId":"NCT07377838","phase":"PHASE3","title":"Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"EHL Bio Co., Ltd.","startDate":"2026-06","conditions":"Atopic Dermatitis","enrollment":286},{"nctId":"NCT05315726","phase":"NA","title":"The Effects of Muscle Vibration on the Development of Spasticity and Neuroplasticity in a Post-stroke Population","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-06-14","conditions":"Post-stroke Patient in Acute, Sub-acute Phase or Chronic","enrollment":165},{"nctId":"NCT05540327","phase":"PHASE2","title":"The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-09-16","conditions":"Systemic Lupus Erythematosus","enrollment":379},{"nctId":"NCT05162586","phase":"PHASE2","title":"The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-03-31","conditions":"Systemic Lupus Erythematosus","enrollment":456},{"nctId":"NCT06974968","phase":"PHASE2","title":"Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","startDate":"2028-05-25","conditions":"Spinal Cord Injury, Safety, Efficacy","enrollment":60},{"nctId":"NCT07197606","phase":"PHASE2","title":"Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Shanghai IxCell Biotechnology Co., LTD","startDate":"2025-10-01","conditions":"Ischemic Stroke","enrollment":86},{"nctId":"NCT04857034","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-12","conditions":"Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous","enrollment":74},{"nctId":"NCT06920836","phase":"PHASE2","title":"QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study","status":"COMPLETED","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2023-06-21","conditions":"Cough","enrollment":270},{"nctId":"NCT04137562","phase":"PHASE2","title":"Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"EHL Bio Co., Ltd.","startDate":"2019-12-11","conditions":"Atopic Dermatitis","enrollment":118},{"nctId":"NCT02868671","phase":"NA","title":"Acupuncture for Mild Traumatic Brain Injury：A Functional Magnetic Resonance Imaging Study","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-08","conditions":"Acupuncture, Mild Traumatic Brain Injury, MRI","enrollment":66},{"nctId":"NCT05671796","phase":"PHASE2","title":"Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury","status":"UNKNOWN","sponsor":"SENAI CIMATEC","startDate":"2023-04-01","conditions":"Spinal Cord Injuries","enrollment":40},{"nctId":"NCT04124367","phase":"PHASE2","title":"IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE","status":"TERMINATED","sponsor":"Ever Neuro Pharma GmbH","startDate":"2021-06-25","conditions":"Chronic Stroke, Subacute Stroke","enrollment":4},{"nctId":"NCT01300208","phase":"PHASE2","title":"To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-10-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":48},{"nctId":"NCT02768571","phase":"PHASE4","title":"Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-03-14","conditions":"Stroke","enrollment":80},{"nctId":"NCT03134352","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema","status":"COMPLETED","sponsor":"Zai Lab Pty. Ltd.","startDate":"2017-04-26","conditions":"Eczema","enrollment":290},{"nctId":"NCT01737697","phase":"PHASE3","title":"Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2012-11-30","conditions":"Hyperkalemia","enrollment":754},{"nctId":"NCT01500564","phase":"NA","title":"Functional Interest of Non Invasive Brain Stimulation During Physiotherapy at a Subacute Phase Post Stroke (Anodal Protocol): ReSTIM","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2012-01-02","conditions":"Stroke","enrollment":10},{"nctId":"NCT01059149","phase":"PHASE2","title":"Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation of Stroke (RAICup)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-11","conditions":"Nervous System Diseases, Stroke, Cerebrovascular Disorders","enrollment":2},{"nctId":"NCT01333579","phase":"PHASE1","title":"Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2008-02","conditions":"Stroke","enrollment":34},{"nctId":"NCT00796887","phase":"PHASE2","title":"Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2009-04","conditions":"Ischemic Stroke","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Silicified microcrystalline cellulose"],"phase":"phase_3","status":"active","brandName":"Placebo ( subacute phase)","genericName":"Placebo ( subacute phase)","companyName":"ZS Pharma, Inc.","companyId":"zs-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}